1-4 of 4
M. Chris Runken
Close
Sort by
Journal Articles

Clinical and Economic Impact of Red Blood Cell Antigen Alloimmunization on Patients with Hereditary Hemorrhagic Telangiectasia

Eric Gehrie, Elisabet Viayna, Christopher Blanchette, Geralyn Meny, Ghislain Noumsi, Maria Huber, M. Chris Runken
Journal: Blood
Blood (2021) 138 (Supplement 1): 3256.
https://doi.org/10.1182/blood-2021-147173
Published: 2021
Journal Articles

Longer Hospitalizations, Increased Inpatient Mortality and Costs Are Associated with Alloimmunization Among Patients with Myelodysplastic Syndromes

Eric Gehrie, Elisabet Viayna, Christopher Blanchette, Geralyn Meny, Ghislain Noumsi, Maria Huber, M. Chris Runken
Journal: Blood
Blood (2021) 138 (Supplement 1): 1075.
https://doi.org/10.1182/blood-2021-145874
Published: 2021
Journal Articles

Red Cell Alloimmunization Is Associated with Higher Treatment Costs and Poor Health Outcomes Among Hemoglobin S-Beta Thalassemia Patients

Eric Gehrie, Elisabet Viayna, Christopher Blanchette, Geralyn Meny, Ghislain Noumsi, Maria Huber, M. Chris Runken
Journal: Blood
Blood (2021) 138 (Supplement 1): 1076.
https://doi.org/10.1182/blood-2021-147183
Published: 2021
Journal Articles

US Economic Impact of Recombinant FVIII Vs Plasma-Derived FVIII/VWF in Previously Untreated Hemophilia a Patients

Robert F. Sidonio, M. Chris Runken, Ken O'Day, Kellie Meyer, Jeffrey Spears
Journal: Blood
Blood (2017) 130 (Supplement 1): 2088.
https://doi.org/10.1182/blood.V130.Suppl_1.2088.2088
Published: 2017